Abstract 2594
Background
Identifying low risk of disease recurrence in localised ccRCC is key for gatekeeping in the adjuvant therapy enrolment. Uncertainty increases the number of patients required for accrual to achieve statistical power. Current scoring systems are good at identifying very low and very high risk cohorts, but have not been proved to be as effective at accurately predicting disease recurrence in intermediate groups. These patients are perhaps those likely to benefit from intervention in addition to surgery, but many may be treated unnecessarily. Using digital pathology, image analysis and machine learning we sought to stratify for risk in this intermediate category.
Methods
Definiens Tissue studio and Developer XD were utilised for object thresholding to measure tumour cell nuclear morphological features on H&E digitised images from 120 ccRCC training set from UK and 217 ccRCC validation set from Singapore. Multiplexed immunofluorescence (mIF) was performed on 120 cases to co-detect neo-vasculature and pan-T cells. An algorithm was derived to measure spatial relationships between blood vessels and T cells. A statistical model was developed by generalised linear model with spatially adaptive local smoothing algorithm, having specificity prefixed (0.8-1) plus cross validation.
Results
Replacing manual nuclear grade with AI aided tumour cell nuclear morphological features improved the specificity of Leibovich score (LS) from 0.76 to 0.86 and from 0.84 to 0.94 in training and validation sets, respectively. Moreover, tumour microenvironment (TM) parameters significantly improved the specificity up to 0.93 in the training set. The negative predictive values of both LS 5 and 6 were zero, but by applying the algorithm the specificity for LS 5 and 6 cases became 0.93 and 0.40 respectively.
Conclusions
By applying image analysis it is possible to identify lower risk for recurrence patients in a conventionally identified intermediate risk group based on routine ccRCC H&E images, and multiplexed TM features. This approach to pathology should help refine selection of patients for clinical trials and form the basis of future AI-enabled prognostic and predictive algorithms in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Renal Cancer Research Fund and NHS Lothian.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract